Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fycompa in ALS (TMS Biomarker Study)
NCT03793868Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Dec 2018
- Primary completion
- Aug 2020
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of perampanel in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Mayo Clinic. Primary endpoint: Motor Threshold at 4 hours. Started Dec 2018; status: completed.
02
Drugs
perampanel
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03793868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03793868.